This partnership has enabled the company to expertise and share the property of valuable intellectual thus enhancing faster development and effectiveness of its drugs such as Ambien. For example,Sanofi-Aventis enters into an agreement with Prasco to market the Zolpidem Tartrate, a generic version of Ambien that is authorized. The manufacturers also market and sell Ambien through major distribution channels such as independence pharmacies, wholesalers, distributors, managed care providers and chains. Ambien is also marketed in online where worldwide shipping is practice as well as discreet and professional delivery. This has contributed to widening its market in the world at large.
Zolpidem qualifies as an approved short-term drug that treats sleeping disorders, insomnia that is easily deterred yet common in adults. Insomnia is characterized by difficulty in maintaining or falling asleep. It is more of a condition than the diseases; it is either acute, persist for a few days or chronic that persist for months. The increase in stress and use of other substances such as tobacco and caffeine may cause short-term insomnia while chronic insomnia may exist without any physical problems and to others existence of underlying diseases causes it. Therefore it is hard to diagnose insomnia, and it entirely dependent on the testimony of the patient of his or her sleeping schedule. Sleep problems that are independent of other conditions are known as primary insomnia, and those which depends on other conditions like depression are known as secondary insomnia. Waking up too early, difficulty in falling asleep, being tired of waking, feeling sleepy during day time, irritability, loss of memory are among the symptoms of insomnia. As described by the National Institutes of Health, the drug functions by slowing brains activity to allow sleep through the production of a calming effect in the brain. The treatment of Ambien is limited for a period of two weeks or less as it has been approved by the Food and Drugs Administration (FDA).